Connor Clark & Lunn Investment Management Ltd. reduced its position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 55.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 50,100 shares of the company's stock after selling 61,794 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.14% of Harrow worth $1,333,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Harrow by 3.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,356 shares of the company's stock valued at $582,000 after acquiring an additional 585 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Harrow during the 4th quarter valued at $25,000. MetLife Investment Management LLC raised its holdings in Harrow by 5.7% in the 4th quarter. MetLife Investment Management LLC now owns 18,908 shares of the company's stock worth $634,000 after purchasing an additional 1,026 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Harrow by 8.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,076 shares of the company's stock worth $640,000 after purchasing an additional 1,428 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of Harrow by 769.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after purchasing an additional 1,462 shares during the period. Hedge funds and other institutional investors own 72.76% of the company's stock.
Analyst Ratings Changes
HROW has been the topic of several recent research reports. Zacks Research raised Harrow from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Cantor Fitzgerald initiated coverage on Harrow in a report on Friday, July 11th. They set an "overweight" rating and a $76.00 price target on the stock. BTIG Research lifted their target price on shares of Harrow from $62.00 to $63.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. HC Wainwright upped their price target on shares of Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. Finally, William Blair assumed coverage on Harrow in a research report on Tuesday, June 10th. They set an "outperform" rating on the stock. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the stock. According to MarketBeat.com, Harrow has an average rating of "Buy" and an average price target of $64.67.
Check Out Our Latest Research Report on Harrow
Harrow Price Performance
Harrow stock traded up $0.33 during midday trading on Wednesday, reaching $38.56. 322,785 shares of the stock traded hands, compared to its average volume of 482,575. The stock has a market cap of $1.43 billion, a P/E ratio of -154.24 and a beta of 0.41. The stock's fifty day moving average is $33.48 and its 200-day moving average is $28.98. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78. Harrow, Inc. has a 12 month low of $20.85 and a 12 month high of $59.23.
Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The business had revenue of $63.74 million for the quarter, compared to analysts' expectations of $64.23 million. Harrow has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current year.
About Harrow
(
Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Further Reading
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access